miR-96 promotes breast cancer metastasis by suppressing MTSS1

Xie,Wei; Sun,Feng; Chen,Lin; Cao,Xinjian

doi:10.3892/ol.2018.7728

miR-96 promotes breast cancer metastasis by suppressing MTSS1

Authors:
- Wei Xie
- Feng Sun
- Lin Chen
- Xinjian Cao
View Affiliations

Affiliations: Department of Laboratory Medicine, Nantong First People's Hospital, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Laboratory Medicine, Nantong Tumor Hospital, Nantong, Jiangsu 226361, P.R. China, Department of Laboratory Medicine, Nantong Third People's Hospital, Nantong, Jiangsu 226000, P.R. China
Published online on: January 4, 2018 https://doi.org/10.3892/ol.2018.7728
Pages: 3464-3471
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Novel, non-invasive biomarkers with high sensitivity and specificity are critical for breast cancer treatment, and prognosis. MicroRNA (miR)‑96 has been demonstrated to be highly expressed in several solid malignancies, including breast cancer. However, its expression and function in the metastasis and prognosis of breast cancer have not been fully explored, and its regulation mechanisms remain unclear. In the present study, the serum miR‑96 expression in healthy controls, benign and malignant breast cancer types was compared by using reverse transcription‑quantitative polymerase chain reaction. The effect of chemotherapy on miR‑96 expression in breast cancer was also investigated. Result revealed that miR‑96 expression was increased in malignant breast cancer types and reduced in patients following chemotherapy treatment. The effect of miR‑96 manipulation on the migration of breast cancer cells was also investigated by using wound healing, and Transwell migration assays. These results revealed that the induced expression of miR96 led to enhanced wound closing and trans‑membrane cell numbers. By using bioinformatics analysis, western blotting and immunohistochemical staining, the metastasis suppressor‑1 (MTSS1) gene was identified to be the functional target of miR‑96 in the promotion of cell migration. In conclusion, it was identified that miR‑96 exhibited an increased level in serum samples of patients with malignant breast cancer in comparison with benign breast tumor types and health controls and may be substantially reduced by chemotherapy treatment, implying that it may be used as a prognostic marker in breast cancer. miR‑96 overexpression may inhibit migration of breast cancer cells by downregulating MTSS1 expression.

View Figures

View References

1	Huang X, Li X and Xie X, Ye F, Chen B, Song C, Tang H and Xie X: High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast. 30:39–46. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Kakushadze Z, Raghubanshi R and Yu W: Estimating Cost Savings from Early Cancer Diagnosis. SSRN Electronic J. 2017. View Article : Google Scholar
4	Schootman M, Fuortes L and Aft R: Prognosis of metachronous contralateral breast cancer according to stage at diagnosis: The importance of early detection. Breast Cancer Res Treat. 99:91–95. 2006. View Article : Google Scholar : PubMed/NCBI
5	Bucchi L, Belli P, Benelli E, Bernardi D, Brancato B, Calabrese M, Carbonaro LA, Caumo F, Cavallo-Marincola B, Clauser P, et al: Recommendations for breast imaging follow-up of women with a previous history of breast cancer: Position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM. Radiol Med. 121:891–896. 2016. View Article : Google Scholar : PubMed/NCBI
6	Svoronos A, Engelman D and Slack F: OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
7	Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS and Mirkin CA: Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci USA. 113:pp. 10655–10660. 2016; View Article : Google Scholar : PubMed/NCBI
8	Kang J, Kim W, Lee S, Kwon D, Chun J, Son B, Kim E, Lee JM, Youn H and Youn B: TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene. 36:1585–1596. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, et al: Genome-wide microRNA analysis identifies miR-188-3p as novel prognostic marker and molecular factor involved in colorectal carcinogenesis. Clin Cancer Res. 23:1323–1333. 2016. View Article : Google Scholar : PubMed/NCBI
10	Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ: Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
11	Liu M, Yang R, Urrehman U, Ye C, Yan X, Cui S, Hong Y, Gu Y, Liu Y, Zhao C, et al: miR-19b suppresses PTPRG to promote breast tumorigenesis. Oncotarget. 7:64100–64108. 2016.PubMed/NCBI
12	Li C, Li J, Cai Q, Qiu QQ, Yan M, Liu BY and Zhu ZG: miRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 108:89–92. 2013. View Article : Google Scholar : PubMed/NCBI
13	Qi Y, Cui L, Ge Y, Shi Z, Zhao K, Guo X, Yang D, Yu H, Cui L, Shan Y, et al: Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect Dis. 12:3842012. View Article : Google Scholar : PubMed/NCBI
14	Adhami M, Haghdoost AA, Sadeghi B and Malekpour Afshar R: Candidate miRNAs in human breast cancer biomarkers: A systematic review. Breast Cancer. Nov 3–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
15	Ohzawa H, Miki A, Teratani T, Shiba S, Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, et al: Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett. 13:1731–1740. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F and Yousefi M: The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 78:129–139. 2016. View Article : Google Scholar : PubMed/NCBI
17	Mar-Aguilar F, Rodríguez-Padilla C and Reséndez-Pérez D: Use of serum-circulating miRNA profiling for the identification of breast cancer biomarkers. Methods Mol Biol. 1165:71–80. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhang L, Xu Y, Jin X, Wang Z, Wu Y, Zhao D, Chen G, Li D, Wang X, Cao H, et al: A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer. Breast Cancer Res Treat. 154:423–434. 2015. View Article : Google Scholar : PubMed/NCBI
19	Huo D, Clayton WM, Yoshimatsu TF, Chen J and Olopade OI: Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 7:55231–55248. 2016. View Article : Google Scholar : PubMed/NCBI
20	Cheung CC, Lun SW, Chung GT, Chow C, Lo C, Choy KW and Lo KW: MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma. BMC Cancer. 16:4952016. View Article : Google Scholar : PubMed/NCBI
21	Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, Mamidipally C, Noronha S, Kannan S and Shirsat NV: Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther. 6:521–529. 2010. View Article : Google Scholar : PubMed/NCBI
22	Leung WK, He M, Chan AW, Law PT and Wong N: Wnt/β-Catenin activates miR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett. 362:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
23	Rapti S, Kontos CK, Papadopoulos IN and Scorilas A: High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. Tumour Biol. 37:11815–11824. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xu L, Zhong J, Guo B, Zhu Q, Liang H, Wen N, Yun W and Zhang L: miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol. 37:12023–12032. 2016. View Article : Google Scholar : PubMed/NCBI
25	Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X and Song L: Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 5:e157972010. View Article : Google Scholar : PubMed/NCBI
26	Xu D, He X, Chang Y, Xu C, Jiang X, Sun S and Lin J: Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells. Oncol Rep. 29:653–661. 2013. View Article : Google Scholar : PubMed/NCBI
27	Haflidadottir BS, Larne O, Martin M, Persson M, Edsjö A, Bjartell A and Ceder Y: Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
28	Song HM, Luo Y, Li DF, Wei CK, Hua KY, Song JL, Xu H, Maskey N and Fang L: MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Int J Clin Exp Pathol. 8:9889–9900. 2015.PubMed/NCBI
29	Gao F and Wang W: MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a. Mol Med Rep. 11:1200–1206. 2015. View Article : Google Scholar : PubMed/NCBI
30	Lee YG, Macoska JA, Korenchuk S and Pienta KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia. 4:291–294. 2002. View Article : Google Scholar : PubMed/NCBI
31	Huang XY, Huang ZL, Xu B, Chen Z, Re TJ, Zheng Q, Tang ZY and Huang XY: Elevated MTSS1 expression associated with metastasis and poor prognosis of residual hepatitis B-related hepatocellular carcinoma. J Exp Clin Cancer Res. 35:852016. View Article : Google Scholar : PubMed/NCBI
32	Li XD, Zhang JX, Jiang LJ, Wang FW, Liu LL, Liao YJ, Jin XH, Chen WH, Chen X, Guo SJ, et al: Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. Oncogene. 35:6281–6292. 2016. View Article : Google Scholar : PubMed/NCBI
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
34	Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z and Zhu Q: miR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res. 16:4732014. View Article : Google Scholar : PubMed/NCBI
35	Guo Y, Ren M, Shang C, Zhu L and Zhong M: MTSS1 gene regulated by miR-96 inhibits cell proliferation and metastasis in tongue squamous cellular carcinoma Tca8113 cell line. Int J Clin Exp Med. 8:15441–15449. 2015.PubMed/NCBI
36	Giacobbe A, Compagnone M, Bongiorno-Borbone L, Antonov A, Markert EK, Zhou JH, Annicchiarico-Petruzzelli M, Melino G and Peschiaroli A: p63 controls cell migration and invasion by transcriptional regulation of MTSS1. Oncogene. 35:1602–1608. 2016. View Article : Google Scholar : PubMed/NCBI
37	Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, et al: EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal. 8:ra292015. View Article : Google Scholar : PubMed/NCBI
38	Zhong J, Shaik S, Wan L, Tron AE, Wang Z, Sun L, Inuzuka H and Wei W: SCF β-TRCP targets MTSS1 for ubiquitination-mediated destruction to regulate cancer cell proliferation and migration. Oncotarget. 4:2339–2353. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, et al: Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res. 12:6702–6708. 2006. View Article : Google Scholar : PubMed/NCBI
40	Parr C and Jiang WG: Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer. 45:1673–1683. 2009. View Article : Google Scholar : PubMed/NCBI
41	Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One. 8:e555022013. View Article : Google Scholar : PubMed/NCBI